No Data
Sapporo Clinical Lab Sees FY Net Y320.00M
Sapporo Clinical Laboratory: Summary of Financial Results for the 3rd Quarter Ending March 31, 2025 [Japanese GAAP] (Consolidated)
Sapporo Clinical Laboratory: Half Year Report - Term 61 (2024/04/01 - 2025/03/31)
Sapporo Clinical Laboratory: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [Japanese GAAP] (consolidated)
Sony Group Corp, Asics, Mitsui Fudosan, Softbank (8th)(5541-9959)
※The calendar above is only a schedule and may be subject to change depending on the company's convenience. --------------------------------------- November 8th (Friday) <5541> Ohira Gold <5631> Nisshin Steel <5644> Metal Art <5706> Mitsui Gold <5711> Mitsubishi Ma <5727> Houg Titanium <5759> Nihon Denka <5816> Onamba <5830>
KDDI announces a 2.3% increase in operating profit in the second quarter to 573 billion yen, along with a share buyback and split.
KDDI<9433> announced its financial results for the second quarter of the fiscal year ending March 2025, with revenue increasing by 2.8% year-on-year to 2 trillion 855.7 billion 13 million yen, and operating profit increasing by 2.3% to 573 billion 86 million yen. The non-communications sectors such as enterprise digital transformation (DX) support services and finance performed well. The financial estimates for the fiscal year ending in March 2025 remain unchanged. Additionally, up to 100 billion yen, equivalent to 1.39% of the total number of issued shares (excluding treasury stock), is 2800.